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Global Alliance for Chronic Disease researchers’ statement on 
multimorbidity
The Global Alliance for Chronic Disease (GACD) is an 
alliance of health research funders whose research 
teams form a network of multidisciplinary health-care 
professionals and researchers. We aim to reduce the 
impact of non-communicable diseases (NCDs) through 
a focus on implementation research in low-income 
and middle-income countries (LMICs) and vulnerable 
populations in high-income countries (HICs).
The GACD has commissioned research on hyper-
tension, diabetes, chronic respiratory diseases, mental 
health, and in 2018, the scale up of hypertension and 
diabetes interventions. We particularly recognise the 
importance and challenge of coexisting physical and 
mental health multimorbidity arising from epidemio-
logical transitions (ie, from communicable to non-
communicable diseases) and rapid population ageing. 
Although our initial programmes have not explicitly 
considered multimorbidity in the context of cancer and 
chronic infectious diseases such as tuberculosis and HIV, 
we recognise that multimorbidity in relation to these 
conditions is also a burgeoning challenge. Notably, very 
little research has been done to address the coexistence 
of and potential for reciprocal interactions between the 
course of NCDs and the natural history of acute or long-
term infections.
Our collaborative approach resulted in the 
realisation that multimorbidity was a challenge for 
all our members. To address this issue, we formed a 
multidisciplinary multimorbidity working group, listed 
in the appendix, with the aim of identifying common 
themes and developing a researchers’ statement 
on multimorbidity. The full version of the GACD 
Researchers’ Statement1 highlights the specific data 
that we considered when collating these themes, and 
an exemplar case history that illustrates the challenges 
for those living with multimorbidity in LMICs. The 
six common themes identified of importance across 
all our research programmes are: (1) the relevance of 
multimorbidity to all health-care professionals; (2) 
the general under-recognition of multimorbidity in 
health-care provision and research, including research 
to explore new models of delivery of care; (3) the 
absence of evidence-based guidelines on approaches 
to manage patients with multimorbidity leading to 
undertreatment, mistreatment, and overtreatment 
(in part driven by the absence of primary evidence due 
to exclusion of many people with multimorbidity from 
efficacy trials); (4) the need to provide greater access to 
expert, proactive holistic primary care that integrates 
NCDs; (5) the need for improved integration of health-
care education, both to health-care providers and 
to patients and their families, specifically in relation 
to multimorbidity and including how to best access 
current models of care; and (6) the need for further 
research assessing interventions that address the 
challenge of multimorbidity in LMIC settings (eg, low-
cost combination interventions and holistic prevention 
programmes).
The following statement summarised our deliberations: 
“The GACD research network believes that a greater 
focus on multimorbidity is overdue and necessary to 
successfully improve global health outcomes”.1 To achieve 
the GACD aim of reducing the impact of multimorbidity 
in LMICs with a switch to healthy active ageing, we 
identified three strategic objectives.
The first objective is greater policy awareness and 
focus on multimorbidity through integrated proactive 
chronic care, rather than systems that address single 
NCDs. Practical examples of how this objective could be 
achieved include support for education, training, and 
guideline development that focus on multimorbidity, 
and policies that make implementation of simple 
universal interventions—around diet, exercise, reduced 
exposure to tobacco, indoor and outdoor air pollution, 
and alcohol—attractive, effective, and practical to 
implement.
The second objective proposes changes in the way 
that research is commissioned, funded, and delivered 
when considering NCDs in LMICs, particularly the 
promotion of working across and between traditional 
disease, primary care, and specialist boundaries. 
Pragmatic trial designs are one approach to ensure the 
effects of interventions are considered holistically, in the 
situations in which they are developed and treated with 
shared data dictionaries of disease and broad outcome 
definitions.
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Finally, the third objective aims to have health systems 
research aligned with universal health coverage. In 
particular, we aim to improve consideration of the 
role of proactive primary care and (where appropriate) 
community health workers in developing knowledge and 
skills to deliver effective integrated care of multimorbid 
NCDs. Addressing multimorbidity will help improve 
health systems and their efficiency, particularly when 
such systems are weak or fragmented.
We present the case for a greater focus on 
multimorbidity, specifically in relation to non-
communicable diseases in LMICs and vulnerable 
populations in HICs. The current disease-specific 
approaches hinder research and patient care and the 
ability to maximise improvements in health outcomes. 
Only by working collaboratively will we be able to achieve 
international health targets such as the 2030 Sustainable 
Development Goals, especially those in relation to 
NCDs, mental health, and long-term communicable 
diseases. Success will require working across traditional 
boundaries and the GACD network provides a practical 
example of how this can work. With our latest funding 
call in relation to scale-up of hypertension and diabetes 
research in partnership with delivery organisations, 
our shared data dictionaries, and our multidisciplinary 
working groups, the GACD is leading the development 
of novel approaches to address multimorbidity in LMICs.
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